FDA denies a petition to exempt certain radiology AI software from 510(k) review, stressing ongoing regulatory oversight.
Key Details
- 1FDA rejected Harrison.ai's petition seeking 510(k) exemption for four types of radiology AI (CADx, CADe, CADt, CADe/x) under specific classifications.
- 2At least 255 radiology AI devices received 510(k) clearance in 2025 alone, per FDA records.
- 3FDA clarified prior clearance does not guarantee manufacturer competence for future device development.
- 4Manufacturer-proposed self-evaluation and risk plans were dismissed due to insufficient FDA oversight mechanisms.
- 5Most public comments opposed the exemption, and FDA detailed significant differences between CADe, CADx, and CADe/x devices impacting regulatory needs.
- 6The agency emphasized vulnerabilities in relying on end-users (radiologists) to catch all performance issues.
Why It Matters
This decision underscores the FDA’s commitment to robust regulatory oversight for radiology AI, potentially affecting product development timelines and market strategies. The nuanced treatment of different device categories and the rejection of broad user detection arguments highlight stringent evidentiary requirements that developers must meet.
Source
AuntMinnie
Related News
•Radiology Business
Everlywell Launches Direct-to-Consumer Mammography AI for Breast Cancer Risk
Everlywell now offers the FDA-authorized Clairity Breast AI tool for patients to assess breast cancer risk from their mammograms.
•Radiology Business
GE HealthCare Appoints Chief AI Officer to Lead Imaging Innovation
GE HealthCare has hired Rodolphe Katra as its new global chief AI officer to drive its AI strategy in imaging.
•Radiology Business
Sweden Deploys AI as Standalone Second Reader for Mammography
Three Stockholm hospitals will adopt AI to fully replace radiologist second reads in breast cancer screening.